Last update 06 Jul 2026

HSK41959

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
HSK41959
Target
PRMT5
Action
inhibitors
Mechanism
PRMT5 inhibitors(Protein arginine methyltransferase 5 inhibitors)
Therapeutic Areas
Neoplasms
Active Indication
Methylthioadenosine phosphorylase deletion cancerLocally Advanced Malignant Solid Neoplasm
Inactive Indication-
Originator Organization
Shanghai Haisishengnuo Pharmaceutical Technology Co., Ltd
Active Organization
Haisco Pharmaceutical Group Co., Ltd.Haisco Pharmaceutical Group Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with HSK41959
NCT06968572
/ RecruitingPhase 1
A Phase I, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of HSK41959 in Patients With MTAP Deletion Locally Advanced or Metastatic Solid Tumors
CTR20262588
/ Not yet recruitingPhase 1
评价 HSK41959片与标准治疗联合治疗MTAP缺失的晚期实体瘤患者中的安全性、耐受性、药代动力学和有效性的Ib期临床研究
[Translation] A phase Ib clinical study evaluating the safety, tolerability, pharmacokinetics, and efficacy of HSK41959 tablets in combination with standard therapy for patients with MTAP-deficient advanced solid tumors.
100 Clinical Results associated with HSK41959
Login to view more data
100 Translational Medicine associated with HSK41959
Login to view more data
100 Patents (Medical) associated with HSK41959
Login to view more data
100 Deals associated with HSK41959
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Methylthioadenosine phosphorylase deletion cancerPhase 1
China
Haisco Pharmaceutical Group Co., Ltd.Haisco Pharmaceutical Group Co., Ltd.
06 Jul 2026
Locally Advanced Malignant Solid NeoplasmPhase 1
China
Haisco Pharmaceutical Group Co., Ltd.Haisco Pharmaceutical Group Co., Ltd.
11 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT06968572 (ASCO2026)
Phase 1
Methylthioadenosine phosphorylase deletion cancer
MTAP-deleted
19
bvllwsnmbq(mrturtxecl) = opjihzyqik dpxfmtlbds (hbmfpklpwq )
View more
Positive
29 May 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free